Subcutaneous Administration of Glutathione
Subcutaneous (SC) administration of glutathione is not an established or routinely recommended route of use for humans. (fda.gov)
FDA has raised safety concerns with injectable glutathione preparations compounded from dietary glutathione ingredients due to reports of adverse events attributed to potentially excessive bacterial endotoxin levels. (fda.gov)
Evidence for the Route of Administration
Evidence supporting glutathione use in humans has largely involved non-SC routes for supplementation or investigational use rather than SC injection. (fda.gov)
No regulatory documentation supports SC glutathione injection as a standard, approved therapy. (fda.gov)
Regulatory and Quality Considerations
FDA cautioned that glutathione L-reduced powder intended for dietary supplement use was not intended for use in sterile drugs when compounded into injectable formulations. (fda.gov)
FDA reported adverse events in seven patients who received injectable glutathione compounded from this source, with symptoms consistent with reactions to excessive endotoxin exposure. (fda.gov)
FDA testing found excessive bacterial endotoxin in glutathione powder samples, with some results reported as high as five times the appropriate limit calculated for IV dosing. (fda.gov)
Safety Issues Relevant to Any Injection Route
Exposure to inappropriate endotoxin levels in an injectable product raises safety risks including fever and chills and potentially severe outcomes. (fda.gov)
Injection-site and infusion-related tolerability issues have been described across glutathione clinical safety discussions, including in FDA review materials addressing injectable formulations. (fda.gov)
Indications and Clinical Use
SC glutathione injection is not supported by FDA approval as a generally accepted indication or route for treatment. (fda.gov)
Common Pitfalls to Avoid
Compounding glutathione injectable products from dietary-supplement glutathione ingredients is associated with quality and endotoxin safety concerns identified by FDA. (fda.gov)
Using unvalidated formulations for injection without route-appropriate sterile manufacturing controls increases the risk of harmful contamination or endotoxin exposure. (fda.gov)
Practical Safety Approach for Clinical Decision-Making
Glutathione intended for parenteral administration should be limited to products with appropriate regulatory status and manufacturing controls for the exact route of administration. (fda.gov)
When a parenteral glutathione route is considered, clinicians and pharmacists should prioritize FDA-identified sterile compounding risks and require evidence of route-appropriate endotoxin and sterility assurance. (fda.gov)